Santhera’s partner Catalyst Pharmaceuticals launches Agamree (vamorolone) in the United States to treat Duchenne muscular dystrophy
Santhera Pharmaceuticals is pleased to note the launch of Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in the United States by Catalyst Pharmaceuticals, Inc. the… read more.